REGN

Regeneron's stock price has fluctuated, trading around $714.89 as of May 8, 2026, down 7.82% over the past 30 days but up 30.53% over the past 12 months. Recent events include the first-quarter 2026 earnings report with revenue of US$3,605.4 million and net income of US$727.2 million, affirmation of a quarterly dividend of US$0.94 per share, completion of a US$2.31 billion buyback, authorization of a new US$3.00 billion share repurchase program, FDA approvals expanding Dupixent and granting accelerated approval for Otarmeni, competition and pricing pressure on Eylea, and new data supporting Dupixent's potential use in COPD.